Fig. 5: Association between HistoTME-based TME classification and overall survival outcomes of SUNY NSCLC patients treated with first-line anti-PD1/PD-L1 therapy (first-line IO patients). | npj Precision Oncology

Fig. 5: Association between HistoTME-based TME classification and overall survival outcomes of SUNY NSCLC patients treated with first-line anti-PD1/PD-L1 therapy (first-line IO patients).

From: Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images

Fig. 5

A Kaplan–Meier plot depicting overall survival−defined as time from date of diagnosis to date of death—of patients that received first-line anti-PD1/PD-L1 treatment. B Kaplan–Meier plot depicting overall survival of SUNY patients that received first-line anti-PD1/PD-L1 therapy stratified by PD-L1 IHC expression. C–E Kaplan–Meier plots depicting overall survival of first-line patients in PD-L1 negative (TPS < 1%), PD-L1 low (TPS = 1–49%) and PD-L1 high (≥50%), cases. Significance of survival differences between distinct subgroups of patients was determined by the log-rank test.

Back to article page